Our current research focuses on:
- Small-molecule inhibitors of human blood coagulation factors for the development of safer anticoagulant therapies.
- Plasma kallikrein inhibitors for the treatment of hereditary angioedema.
- Peptidomimetic P2X1 receptor ligands to modulate platelet activation and thrombus formation.
- Covalent inhibitors of the SARS-CoV-2 main protease for antiviral drug discovery.
- Prostate-specific antigen (PSA) inhibitors as a non-hormonal male contraceptive strategy.
- Cryo-EM structure elucidation of human blood coagulation factors to enable structure-based drug design.
- Microscale parallel synthesis and direct-to-biology approaches for rapid discovery of serine protease inhibitors.
- Total synthesis of natural products and their derivatisation for drug discovery.
[Picture]
Figure 1. Spontaneous recovery of thrombin (acyl-thrombin complex hydrolysis).
[Picture]
Figure 2. Covalent mechanism of α-thrombin inhibition by acylated aminotriazoles